Cyclophosphamide plus cisplatin versus cyclophosphomide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis

G. A. Omura, M. Buyse, S. Marsoni, K. Bertelsen, P. F. Conte, A. Jakobsen, J. Vermorken

Research output: Contribution to journalArticlepeer-review

Abstract

Four randomized clinical trials comparing cyclophosphamide plus cisplatin (CP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP) individually failed to show a significant survival difference in the treatment of ovarian carcinoma. However, by pooling 1,194 patients from these trials in a meta-analysis, there is a statistically significant survival benefit for CAP (P = .02); in addition, there is a significant advantage for CAP in frequency of negative second-look laparotomy (CAP, 30%; CP, 23%; P = .01). Because the dose intensity of CAP was greater than CP in three of the trials, it remains unresolved to what extent the benefit of CAP is from greater dose intensity and to what extent it is from the doxorubicin itself. Either interpretation suggests directions for improving the chemotherapy of ovarian carcinoma.

Original languageEnglish
Pages (from-to)1668-1674
Number of pages7
JournalJournal of Clinical Oncology
Volume9
Issue number9
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Cyclophosphamide plus cisplatin versus cyclophosphomide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis'. Together they form a unique fingerprint.

Cite this